Financhill
Sell
50

AGEN Quote, Financials, Valuation and Earnings

Last price:
$6.22
Seasonality move :
-11.05%
Day range:
$6.45 - $7.04
52-week range:
$1.38 - $18.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.15x
P/B ratio:
--
Volume:
1.6M
Avg. volume:
1.8M
1-year change:
-56.22%
Market cap:
$187.3M
Revenue:
$103.5M
EPS (TTM):
-$28.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AGEN
Agenus
$49.7M $1.35 5.11% -71.03% $11.50
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
ANIP
ANI Pharmaceuticals
$187.3M $1.39 35.6% 68.6% $81.57
ARMP
Armata Pharmaceuticals
$1.4M -$0.39 -- -56% $9.00
CATX
Perspective Therapeutics
$170.4K -$0.29 -- -55.87% $14.1071
PLX
Protalix BioTherapeutics
$13.5M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AGEN
Agenus
$6.83 $11.50 $187.3M -- $0.00 0% 1.15x
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
ANIP
ANI Pharmaceuticals
$64.96 $81.57 $1.4B 55.43x $0.00 0% 1.88x
ARMP
Armata Pharmaceuticals
$2.29 $9.00 $82.9M -- $0.00 0% 917.38x
CATX
Perspective Therapeutics
$4.0000 $14.1071 $296.9M -- $0.00 0% 28.19x
PLX
Protalix BioTherapeutics
$1.42 $14.00 $113M 35.50x $0.00 0% 1.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AGEN
Agenus
-10.89% 3.671 56.5% 0.09x
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
ANIP
ANI Pharmaceuticals
58.41% -0.735 42.22% 1.86x
ARMP
Armata Pharmaceuticals
-- 2.403 -- --
CATX
Perspective Therapeutics
-- 1.363 -- --
PLX
Protalix BioTherapeutics
-- -1.225 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AGEN
Agenus
$2.4M -$13.3M -- -- -56.41% -$25.6M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
ANIP
ANI Pharmaceuticals
$124.1M $14.1M -2.24% -4.66% 12.92% $15.1M
ARMP
Armata Pharmaceuticals
-- -$8.2M -- -- -- -$7.7M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Agenus vs. Competitors

  • Which has Higher Returns AGEN or AIM?

    AIM ImmunoTech has a net margin of -104.99% compared to Agenus's net margin of -10571.43%. Agenus's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    AGEN
    Agenus
    10% -$20.60 -$288.8M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About AGEN or AIM?

    Agenus has a consensus price target of $11.50, signalling upside risk potential of 68.38%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Agenus, analysts believe AIM ImmunoTech is more attractive than Agenus.

    Company Buy Ratings Hold Ratings Sell Ratings
    AGEN
    Agenus
    1 3 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is AGEN or AIM More Risky?

    Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock AGEN or AIM?

    Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AGEN or AIM?

    Agenus quarterly revenues are $24.1M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Agenus's net income of -$25.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Agenus's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.15x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AGEN
    Agenus
    1.15x -- $24.1M -$25.3M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns AGEN or ANIP?

    ANI Pharmaceuticals has a net margin of -104.99% compared to Agenus's net margin of 7.96%. Agenus's return on equity of -- beat ANI Pharmaceuticals's return on equity of -4.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    AGEN
    Agenus
    10% -$20.60 -$288.8M
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
  • What do Analysts Say About AGEN or ANIP?

    Agenus has a consensus price target of $11.50, signalling upside risk potential of 68.38%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $81.57 which suggests that it could grow by 25.57%. Given that Agenus has higher upside potential than ANI Pharmaceuticals, analysts believe Agenus is more attractive than ANI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AGEN
    Agenus
    1 3 0
    ANIP
    ANI Pharmaceuticals
    3 1 0
  • Is AGEN or ANIP More Risky?

    Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.195%.

  • Which is a Better Dividend Stock AGEN or ANIP?

    Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

  • Which has Better Financial Ratios AGEN or ANIP?

    Agenus quarterly revenues are $24.1M, which are smaller than ANI Pharmaceuticals quarterly revenues of $197.1M. Agenus's net income of -$25.3M is lower than ANI Pharmaceuticals's net income of $15.7M. Notably, Agenus's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.15x versus 1.88x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AGEN
    Agenus
    1.15x -- $24.1M -$25.3M
    ANIP
    ANI Pharmaceuticals
    1.88x 55.43x $197.1M $15.7M
  • Which has Higher Returns AGEN or ARMP?

    Armata Pharmaceuticals has a net margin of -104.99% compared to Agenus's net margin of --. Agenus's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AGEN
    Agenus
    10% -$20.60 -$288.8M
    ARMP
    Armata Pharmaceuticals
    -- -$0.20 --
  • What do Analysts Say About AGEN or ARMP?

    Agenus has a consensus price target of $11.50, signalling upside risk potential of 68.38%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 293.01%. Given that Armata Pharmaceuticals has higher upside potential than Agenus, analysts believe Armata Pharmaceuticals is more attractive than Agenus.

    Company Buy Ratings Hold Ratings Sell Ratings
    AGEN
    Agenus
    1 3 0
    ARMP
    Armata Pharmaceuticals
    0 0 0
  • Is AGEN or ARMP More Risky?

    Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

  • Which is a Better Dividend Stock AGEN or ARMP?

    Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AGEN or ARMP?

    Agenus quarterly revenues are $24.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Agenus's net income of -$25.3M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Agenus's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.15x versus 917.38x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AGEN
    Agenus
    1.15x -- $24.1M -$25.3M
    ARMP
    Armata Pharmaceuticals
    917.38x -- -- -$6.5M
  • Which has Higher Returns AGEN or CATX?

    Perspective Therapeutics has a net margin of -104.99% compared to Agenus's net margin of --. Agenus's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AGEN
    Agenus
    10% -$20.60 -$288.8M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About AGEN or CATX?

    Agenus has a consensus price target of $11.50, signalling upside risk potential of 68.38%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 252.68%. Given that Perspective Therapeutics has higher upside potential than Agenus, analysts believe Perspective Therapeutics is more attractive than Agenus.

    Company Buy Ratings Hold Ratings Sell Ratings
    AGEN
    Agenus
    1 3 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is AGEN or CATX More Risky?

    Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock AGEN or CATX?

    Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AGEN or CATX?

    Agenus quarterly revenues are $24.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Agenus's net income of -$25.3M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Agenus's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.15x versus 28.19x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AGEN
    Agenus
    1.15x -- $24.1M -$25.3M
    CATX
    Perspective Therapeutics
    28.19x -- -- -$18.2M
  • Which has Higher Returns AGEN or PLX?

    Protalix BioTherapeutics has a net margin of -104.99% compared to Agenus's net margin of -35.79%. Agenus's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    AGEN
    Agenus
    10% -$20.60 -$288.8M
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About AGEN or PLX?

    Agenus has a consensus price target of $11.50, signalling upside risk potential of 68.38%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 885.92%. Given that Protalix BioTherapeutics has higher upside potential than Agenus, analysts believe Protalix BioTherapeutics is more attractive than Agenus.

    Company Buy Ratings Hold Ratings Sell Ratings
    AGEN
    Agenus
    1 3 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is AGEN or PLX More Risky?

    Agenus has a beta of 1.511, which suggesting that the stock is 51.137% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

  • Which is a Better Dividend Stock AGEN or PLX?

    Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AGEN or PLX?

    Agenus quarterly revenues are $24.1M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Agenus's net income of -$25.3M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Agenus's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 1.15x versus 1.99x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AGEN
    Agenus
    1.15x -- $24.1M -$25.3M
    PLX
    Protalix BioTherapeutics
    1.99x 35.50x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock